{"id":"W2115330744","doi":"10.1093/annonc/mdq020","title":"Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Gemcitabine; Hazard ratio; Clinical endpoint; Internal medicine; Placebo; Lung cancer; Oncology; Cisplatin; Progression-free survival; Chemotherapy; Confidence interval; Surgery; Urology; Gastroenterology; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002638464,0.001978523,0.005350374,0.0007588262,0.0006138067,0.001528856,0.001282113,0.002769051,0.01017266],"category_scores_gemma":[0.002467722,0.001073456,0.003725007,0.0008721412,0.001954716,0.002327906,0.0008593132,0.005821549,0.001656948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001536777,"about_ca_system_score_gemma":0.001502273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001876871,"about_ca_topic_score_gemma":0.004233189,"domain_scores_codex":[0.9988831,0.0006313598,0.00006584418,0.0002106111,0.00005588671,0.0001532524],"domain_scores_gemma":[0.9985715,0.0004465957,0.0002585438,0.0001219894,0.00006112778,0.0005401197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9865664,0.001964233,0.0002394711,0.0003600601,0.0006443725,0.00001407286,0.00003388683,0.000313925,0.0009924864,0.00004135336,0.0004083046,0.008421432],"study_design_scores_gemma":[0.9639728,0.03400359,0.0008160865,0.00002460153,0.000477714,0.00001708195,0.00001385031,0.000141906,0.000176399,0.00007429195,0.0002721683,0.000009491139],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9793984,0.008906656,0.0008030517,0.001704417,0.001076113,0.003339052,0.001992942,0.0001943899,0.002584867],"genre_scores_gemma":[0.9806958,0.004810794,0.0017642,0.001382775,0.0006709941,0.004138148,0.002090857,0.00007519541,0.004371244],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01017266,"threshold_uncertainty_score":0.03403097,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0480325960961244,"score_gpt":0.4125897085681237,"score_spread":0.3645571124719993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}